Latest 10-Q quarterly reports

ImageneBio, Inc. filed its Q2 2026 Form 10-Q, detailing continued investment in its lead drug candidate, olevaprubart, while reporting net losses and a material weakness in internal controls.

Gibraltar Industries reported a net loss of $59.3 million for the six months ended June 30, 2026, despite a substantial increase in net sales driven by the OmniMax acquisition.

UroGen Pharma Ltd. announced substantial revenue increases driven by Zusduri sales, alongside continued investment in its product pipeline and operational expansion.

Trinity Capital Inc. details a significant expansion in its investment portfolio and robust growth in investment income for the period ending June 30, 2026.

One Stop Systems (OSS) reported a substantial increase in revenue for Q2 2026, driven by new customer wins and program ramp-ups, but also disclosed a significant $6.25 million legal settlement impacting its financial results.

Vishay Intertechnology, Inc. announced a significant increase in net revenues and net earnings for the fiscal quarter ended July 4, 2026, driven by higher sales volumes and improved pricing.

Zeta Global Holdings Corp. announced a significant 43.5% year-over-year revenue increase for the second quarter of 2026, driven by new and existing customer growth and the Marigolds Enterprise Business acquisition.

Immuneering Corporation reported progress in its atebimetinib clinical trials, including positive interim data, while also detailing increased operating expenses and a continued net loss.

Lakeland Financial Corporation announced a significant increase in net income and diluted EPS for the second quarter and first six months of 2026, driven by higher net interest income and improved fee-based revenues.

Bioventus Inc. announced robust financial results for the second quarter of 2026, showcasing significant revenue increases and improved net income, driven by strong performance in its U.S. Pain Treatments segment.

Holley Inc. announced its second quarter 2026 financial results, showing a modest increase in net sales but a significant decline in operating income and net income, largely due to substantial losses from asset divestitures and increased operating expenses.

NCR Voyix Corporation's Q2 2026 Form 10-Q filing reveals a continued year-over-year revenue decrease, primarily driven by the transition of its hardware business, alongside a net loss, though recurring revenue and gross margin percentage showed improvement.

Latham Group, Inc. announced a 14.4% increase in net sales for the fiscal quarter ended June 27, 2026, reaching $197.5 million, driven by volume and pricing, though net income decreased by $3.2 million to $12.8 million.

Dine Brands Global reported a revenue increase in Q2 2026 driven by company-owned restaurant acquisitions, though net income declined due to higher operating costs and interest expenses.

Rapport Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in R&D and a significant collaboration agreement.

Lifecore Biomedical, Inc. reported a decrease in total revenues and a widening net loss for the second quarter of 2026, impacted by a significant decline in CDMO services.

Verano Holdings Corp. announced its second quarter 2026 financial results, showing an 8% increase in revenue but a decline in gross profit margin and a wider net loss compared to the prior year period.

Kymera Therapeutics announced significant collaboration revenue from Gilead and Sanofi, alongside continued investment in R&D, leading to a net loss.

Shake Shack Inc. filed its Q2 2026 Form 10-Q, detailing a 17.5% increase in Shack sales and a 3.5% rise in same-Shack sales, alongside a 34.3% surge in digital sales.

Entrada Therapeutics reported encouraging early functional data from its ENTR-601-44 Phase 1/2 trial for Duchenne Muscular Dystrophy, while noting a cash runway into Q3 2027.

Q32 Bio Inc. reported progress in its bempikibart program for alopecia areata, alongside significant capital raises and a reduction in operating expenses.

Match Group reported a slight year-over-year revenue decrease for Q2 2026, but demonstrated improved operating income and Adjusted EBITDA, driven by strong performance in Hinge and cost management.

Lineage, Inc. filed its Q2 2026 10-Q, showing revenue growth in Global Warehousing offset by declines in Global Integrated Solutions, leading to a net loss.

NewAmsterdam Pharma Company N.V. reported its second-quarter 2026 financial results, showing a significant decrease in revenue and an increase in net loss, while advancing its obicetrapib development programs.

Orthofix Medical Inc. announced its second quarter 2026 financial results, showing a 3.8% increase in net sales to $210.9 million, but a net loss of $15.8 million.

Flutter Entertainment plc announced its Q2 2026 results, showing a 3% revenue increase to $4,326 million but a significant drop in operating profit to a $144 million loss, leading to a net loss of $296 million.

The Brinks Company reported a 7% increase in Q2 2026 revenues driven by currency tailwinds and organic growth across segments, though acquisition-related expenses impacted operating profit.

Shopify Inc. announced a significant increase in revenue and net income for the second quarter of 2026, driven by strong merchant solutions performance and a rebound in investment gains.

SharkNinja Inc. announced a significant increase in net sales for the second quarter of 2026, driven by robust performance across all product categories and geographic regions.

Eos Energy Enterprises, Inc. (EOSE) filed its Form 10-Q for the quarter ended June 30, 2026, detailing a significant increase in revenue driven by product deliveries and a new related-party contract, alongside substantial operating losses and ongoing legal actions.